Clinical Effect of Rebamipide on Chronic Gastritis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02393430

Enrollment

180

Registered

2015-03-19

Start date

2012-05-31

Completion date

2014-06-30

Last updated

2015-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis

Brief summary

To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.

Interventions

DRUGRebamipide

Rebamipide is a

BEHAVIORALoptimization of life style

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* With the symptoms as follow: epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting and so on * diagnosed as chronic gastritis with endoscopic and pathological methods * agree to join in this clinical trail

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
modified Lanza score	26 weeks	—
visual Analog scale	26 weeks	to describe the inflamamtory of gastric mucosa pathologically

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026